Please login to the form below

Not currently logged in
Email:
Password:

heart failure

This page shows the latest heart failure news and features for those working in and with pharma, biotech and healthcare.

J&J’s Invokana first SGLT2 to show kidney disease benefits

J&J’s Invokana first SGLT2 to show kidney disease benefits

Results from the CREDENCE study, which evaluated type 2 diabetes patients with chronic kidney disease, showed that those taking the once-daily pill had a 30% lower risk of kidney failure, ... The drug also reduced the risk of cardiovascular (CV) death

Latest news

  • Amgen, Servier heart failure drug clears trial hurdle Amgen, Servier heart failure drug clears trial hurdle

    than Novartis’ Entresto (sacubitril/valsartan) and Amgen/Servier's Corlanor (ivabradine), which were both approved for heart failure in 2015. ... Amgen recently started phase 1 trials of another Cytokinetics-developed heart failure candidate, cardiac

  • Novartis in-licenses Akcea’s novel cardiovascular therapy Novartis in-licenses Akcea’s novel cardiovascular therapy

    The former, a heart failure treatment, is now gaining momentum after a slow start since its launch in 2015. ... Meanwhile canakinumab, a novel inflammation-targeting treatment to prevent stroke and heart attacks, has now been withdrawn from regulatory

  • Amgen, Servier start second phase 3 trial of heart failure hope Amgen, Servier start second phase 3 trial of heart failure hope

    Treatment is one of few in underserved area. Amgen and Servier have decided to run a second phase 3 trial of omecamtiv mecarbil in heart failure, as their first pivotal study ... One advance in drug treatment was the launch of Novartis’ Entresto

  • Novartis aims for 10 blockbuster launches by 2020 Novartis aims for 10 blockbuster launches by 2020

    Includes new gene therapy Zolgensma. Novartis has posted a 5% increase in its sales in 2018, driven up by strong performances by psoriasis blockbuster Cosentyx and heart failure drug Entresto. ... Entresto - Heart failure with preserved ejection fraction

  • Moderna CEO makes case for firm’s lofty valuation Moderna CEO makes case for firm’s lofty valuation

    Three additional candidates are due to reach the phase 2 testing stage this year, joining Moderna’s AstraZeneca-partnered VEGF-A candidate for heart failure which is its lead project.

More from news
Approximately 35 fully matching, plus 214 partially matching documents found.

Latest Intelligence

  • No incentive for a cure No incentive for a cure

    The paradox of ‘cost-effective but unaffordable’ life-saving medicines. Type 1 diabetes, heart failure, HIV - all examples of diseases that have transitioned from fatal conditions to chronic diseases, thanks to

  • Can value-based healthcare take off and reach for the skies? Can value-based healthcare take off and reach for the skies?

    costs. It was then backed with a ‘no response-no payment’ contract. It has also struck novel reimbursement packages with its heart failure therapy Entresto and its psoriasis treatment Cosentyx.

  • Deal Watch February 2017 Deal Watch February 2017

    Sale of Priority Review Voucher (PRV). 125. Cytokinetics/ Royalty Pharma. 4.5% royalty on global sales of omecamtiv mecarbil for heart failure (phase III).

  • Deal Watch January 2017 Deal Watch January 2017

    1, 700. Ionis | Akcea. Novartis. Exclusive option to licence. AKCEA-APOCIII-LRx for heart failure.

  • A healthy challenge A healthy challenge

    All told, 50 million people in the EU are afflicted by conditions such as diabetes, congestive heart failure, chronic obstructive pulmonary disease and asthma, and in 2013 more than 1.2m

More from intelligence
Approximately 1 fully matching, plus 18 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cogora

Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics